Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02302261
Other study ID # 14-572
Secondary ID
Status Completed
Phase N/A
First received November 24, 2014
Last updated July 25, 2016
Start date January 2015
Est. completion date July 2016

Study information

Verified date July 2016
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Research has shown that pleth variability can be used to assess asthma severity in children with status asthmaticus. The investigators would like to use an FDA-cleared monitor (Masimo Radical 7) which measures Pleth Variability Index (PVI) to see if the degree of PVI can be used to help triage patients who present to the pediatric ED in status asthmaticus.


Description:

Patients with asthma have obstruction to exhalation resulting in hyperinflation of their lungs. This hyperinflation results in a phenomenon known as pulsus paradoxus in which the physiologic drop in blood pressure normally seen with inhalation is exaggerated. Studies have shown that patients with more severe asthma exacerbations (i.e. more hyperinflation) have a greater degree of pulsus paradoxus. Typically, pulsus paradoxus is measured using a sphygmomanometer, however, researchers have demonstrated that it can also accurately be measured using plethysmography, a term known as pleth variability index (PVI). Using this concept, Arnold et al (2008, 2010) showed that a greater degree of pulsus paradoxus correlates with asthma severity.

The investigators' study aims to simplify the association between PVI and asthma severity. The investigators hypothesize the following:

1. Patients with a higher admission PVI will have a higher likelihood of being admitted to the hospital.

2. Patients admitted to the Intensive Care Unit (PICU) will have a higher PVI than patients admitted to a floor.

3. PVI can be accurately used to gauge response to bronchodilator/anti-inflammatory therapy.

4. PVI is as effective as respiratory severity score in predicting asthma severity and in gauging response to bronchodilator therapy.

To do this the investigators will recruit children who present to the pediatric ED in status asthmaticus. They will be connected to a Masimo Radical 7 monitor upon admission to the ED and then again 4 hours later. In addition the investigators will calculate respiratory severity scores at those same time intervals. The investigators will then look at the disposition of the patient upon leaving the ED: discharge to home, admission to an inpatient floor or admission to the ICU.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Diagnosis of asthma or reactive airway disease upon leaving the ED

- Greater than 10 kg

Exclusion Criteria:

- Patients in whom effective pulse oximetry tracings cannot be obtained

- Patients who are diagnosed with conditions other than asthma/reactive airway disease that are known to cause pulsus paradoxus

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Cohen Children's Medical Center of NY New Hyde Park New York

Sponsors (2)

Lead Sponsor Collaborator
Northwell Health Masimo Corporation

Country where clinical trial is conducted

United States, 

References & Publications (6)

Arnold DH, Gebretsadik T, Minton PA, Higgins S, Hartert TV. Assessment of severity measures for acute asthma outcomes: a first step in developing an asthma clinical prediction rule. Am J Emerg Med. 2008 May;26(4):473-9. doi: 10.1016/j.ajem.2007.05.026. — View Citation

Arnold DH, Jenkins CA, Hartert TV. Noninvasive assessment of asthma severity using pulse oximeter plethysmograph estimate of pulsus paradoxus physiology. BMC Pulm Med. 2010 Mar 29;10:17. doi: 10.1186/1471-2466-10-17. — View Citation

Cannesson M, Desebbe O, Rosamel P, Delannoy B, Robin J, Bastien O, Lehot JJ. Pleth variability index to monitor the respiratory variations in the pulse oximeter plethysmographic waveform amplitude and predict fluid responsiveness in the operating theatre. Br J Anaesth. 2008 Aug;101(2):200-6. doi: 10.1093/bja/aen133. Epub 2008 Jun 2. — View Citation

Clark JA, Lieh-Lai M, Thomas R, Raghavan K, Sarnaik AP. Comparison of traditional and plethysmographic methods for measuring pulsus paradoxus. Arch Pediatr Adolesc Med. 2004 Jan;158(1):48-51. — View Citation

Frey B, Freezer N. Diagnostic value and pathophysiologic basis of pulsus paradoxus in infants and children with respiratory disease. Pediatr Pulmonol. 2001 Feb;31(2):138-43. — View Citation

Rayner J, Trespalacios F, Machan J, Potluri V, Brown G, Quattrucci LM, Jay GD. Continuous noninvasive measurement of pulsus paradoxus complements medical decision making in assessment of acute asthma severity. Chest. 2006 Sep;130(3):754-65. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disposition from ED Determine whether a patient was discharged from the ED, admitted to an inpatient floor or admitted to the ICU. 4 hours No
Secondary Comparison to respiratory severity score Is PVI as effective as RSS in determining asthma severity 4 hours No
Secondary Change in disposition within 24 hours Determine if a patient who was discharged home from the ED required readmission to the ED within 1 week. Determine if a patient admitted to the floor or ICU required a change in level of care in the first 24 hours of admission. 1 week No
See also
  Status Clinical Trial Phase
Completed NCT02872597 - Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus Phase 1
Terminated NCT02966184 - Comparison of Albuterol for Status Asthmaticus Phase 4
Enrolling by invitation NCT00750568 - Intravenous Terbutaline in Severe Status Asthmaticus N/A
Completed NCT00124995 - Trial of Terbutaline for the Treatment of Status Asthmaticus in Children Phase 4
Recruiting NCT05819541 - Treating Exacerbations of Asthma With Oral Montelukast in Children Phase 2
Completed NCT01524198 - The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room Phase 2/Phase 3
Terminated NCT02780479 - Steroids in Children Hospitalized With Asthma Phase 4
Withdrawn NCT01403428 - Non Invasive Positive Pressure Ventilation in Status Asthmaticus Phase 2
Terminated NCT00683449 - Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma Phase 2
Withdrawn NCT03219736 - NiPPV in the Treatment of Acute Asthma Exacerbations N/A
Completed NCT00722020 - HFCWO in Hospitalized Asthmatic Children N/A
Withdrawn NCT03338205 - The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus Phase 3
Recruiting NCT01770899 - Evaluation Montelukast in the Treatment of Status Asthmaticus N/A
Withdrawn NCT01188473 - Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus Phase 1
Withdrawn NCT04656587 - BPAP in Pediatric Asthma Pilot Study N/A
Completed NCT04929626 - Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus Phase 1
Completed NCT00623688 - Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital N/A
Recruiting NCT00494572 - Montelukast With Status Asthmaticus, Ages 6-18 Phase 2/Phase 3
Recruiting NCT00491790 - Montelukast With Status Asthmaticus, Ages 2-5 Phase 2/Phase 3
Completed NCT00279786 - B2-Adrenergic Receptor Polymorphisms